German Site Outcomes Of A Novel Presbyopia-Correcting Iol – A Real World Registry Study
Published 2022
- 40th Congress of the ESCRS
Reference: PO146
| Type: Free paper
| DOI:
10.82333/kg7x-1k10
Authors:
Mike P. Holzer 1
, Stephanie Laupp 1
, Caridad Perez-Vives* 2
, Tanja M. Rabsilber 1
1Eye Center Prof. Holzer & Prof. Rabsilber,Weinheim / Mannheim,Germany, 2Alcon Vision LLC,Fort Worth, TX,United States
Purpose
To report the Real World visual and subjective outcomes observed in routine clinical practice at the Eye Center Prof. Holzer & Prof. Rabsilber with the AcrySof IQ Vivity and AcrySof IQ Vivity Toric Extended Vision IOL models DFT015, DFT215, DFT315, DFT415, and DFT515.
Setting
Site-level results from an international, ambispective registry study conducted in Europe, the UK, Australia and New Zealand evaluating the performance of bilaterally implanted AcrySof Vivity and AcrySof Vivity Toric IOL in a real world setting through routine clinical practice.
Methods
This is a sub-analysis of 20 subjects enrolled to date in our clinic and evaluated using local clinical practice standards. After a minimum of 3 months and up to 6 months post-op follow up, subjects implanted with the AcrySof IQ Vivity and AcrySof Vivity Toric IOL underwent visual acuity assessments at a range of functional distances in addition to subjective vision satisfaction and spectacle independence with validated PROMs questionnaires and patient reports of visual disturbances. We present the outcomes observed at 3 months postoperatively.
Results
The Median (Min, Max) photopic binocular VA (in logMAR) UCDVA is 0.149 (0.000, 0.201), UCIVA (66cm) 0.06 (-0.06, 0.22) and UCNVA (40cm) 0.20 (0.00, 0.46) with 75.0% of subjects presenting UCIVA ≥20/25. Median (Min, Max) binocular BCDVA is 0.000 (0.000, 0.097), DCIVA 0.04 (-0.04, 0.24) and DCNVA 0.23 (0.02, 0.42). 90.0% subjects reported never/rarely needing to wear eyeglasses to see at arm’s length, 94.7% far away and 40.0% to see up close. Also, the majority report no difficulty seeing to engage in an activity/hobby that are interested in and are satisfied with their sight; none halos, glare or starbursts were reported by 95.0%, 100.0% and 100.0% respectively. There are no unanticipated AEs to date.
Conclusions
This interim analysis at our site level subjects bilaterally implanted with the AcrySof IQ Vivity and AcrySof IQ Vivity Toric IOL shows very good distance, intermediate and near visual outcomes with high levels of vision patient satisfaction with low needs to wearing spectacles for intermediate and distance activities and also experiencing low to none photic visual disturbances.